Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in